Effect of Unani Medicine Safoof-e-Teen in Zaheer (Dysentery)

Clinical Validation of Unani Pharmacopoeal formulation Safoof e Teen in Zaheer (Dysentery)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015400

Enrollment

240

Registered

2018-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A060- Acute amebic dysentery Health Condition 2: A069- Amebiasis, unspecified Health Condition 3: K00-K95- Diseases of the digestive system

Interventions

Intervention1: Safoof-e-Teen: 7gm twice daily orally To be taken with water after meals for six weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group 18-65 years. 2. Patients of ZahÄ«r (Dysentery) having the following signs and symptoms: (i) 2-8 small-volume, semiformed or unformed stools/day (ii) BarÄ?z DamwÄ« (Bloody Stools) and/or BarÄ?z MukhÄ?tÄ« (Mucoid Stools) (iii) E. histolytica Cysts or Trophozoites in stools With or without any of the following: Maghs (Tenesmus) Wajaâ?? al-Batn Asfal (Lower Abdominal Pain) ÄªlÄ?m al-Batn Asfal (Lower Abdominal Tenderness)

Exclusion criteria

Exclusion criteria: 1. Patients having diarrhoea with >8 stools/day 2. Moderate or severe dehydration 3. Fever (>=101 Â°F) 4. Patients having amoebic dysentery with any associated severe complications, e.g., fulminant colitis with perforation, paralytic ileus, toxic megacolon, ameboma, and liver abscess. 5. Clinical evidence of coexisting acute systemic illnesses 6. History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV infection, chronic liver disease, CKD, coeliac disease, IBD, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 7. Pregnant and lactating women 8. H/o Addiction (alcohol, drugs) 9. H/o Hypersensitivity to the study drug or any of its ingredients

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Safoof-e-Teen in Zaheer (Dysentery)Timepoint: six weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: six weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026